Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming

Paul W. Burridge, Gordon Keller, Joseph D. Gold, Joseph C. Wu*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

402 Scopus citations

Abstract

Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts, highlighting potential applications and future challenges.

Original languageEnglish (US)
Pages (from-to)16-28
Number of pages13
JournalCell stem cell
Volume10
Issue number1
DOIs
StatePublished - Jan 6 2012

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Fingerprint Dive into the research topics of 'Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming'. Together they form a unique fingerprint.

Cite this